Pearl Therapeutics

37 articles about Pearl Therapeutics

• 

  AstraZeneca Opens New Bay Area R&D Site With 400 Employees

  5/24/2018

  After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area. 

• AstraZeneca PLC in Deal for Pearl Therapeutics Worth Up to $1.15 Billion

  6/11/2013

• Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting

  5/17/2013

• Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD

  5/14/2013

• Pearl Therapeutics Receives Award for Innovative Co-Suspension Technology

  3/14/2013

• Pearl Therapeutics Strengthens its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development

  1/17/2013

• Pearl Therapeutics to Present at J.P. Morgan Healthcare Conference

  1/4/2013

• Pearl Therapeutics Successfully Completes Phase 2 Program; Identifies Optimal Dose of PT003 and Its Components for Phase 3

  10/24/2012

• Pearl Therapeutics Completes Phase 2b Study of Glycopyrrolate, Defines Dose-Response Curve and Identifies Optimal Dose of PT001

  9/13/2012

• Pearl Therapeutics Receives TiE50 Award from Global Entrepreneurship Network

  5/21/2012

• Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD

  5/14/2012

• Pearl Therapeutics Creates Nanogram-Dose Inhalers and Initiates a Phase 2b Study to Characterize Ultra-low Doses of Glycopyrrolate

  4/3/2012

• Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003

  1/6/2012

• Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD

  12/7/2011

• Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform

  10/31/2011

• Pearl Therapeutics' Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva(R)

  9/26/2011

• FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech

  9/7/2011

• Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI

  8/31/2011

• Pearl Therapeutics Selects TransPerfect's Trial Interactive as its Electronic Trial Master File (eTMF) Enterprise Solution

  8/23/2011

• Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies

  6/16/2011